Owner Alexion Pharmaceuticals, Inc. United States of America, as represented by The Secretary Department of Health and Human Services

Inventors Pelfrey, Clara M.; Nye, Steven H.; Matis, Louis A.; Mueller, Eileen Elliott; Mueller, John P.; Squinto, Stephen P.; Wilkins, James A.; Lenardo, Michael J.; McFarland, Henry F.

Agent Cullen & Co

Pub. Number AU-B-2003246018

Parent 30223

Filing date 10 September 2003

Wipo publication date 2 October 2003

Acceptance publication date 7 July 2005

C07K 014/435 Peptides having more than 20 amino acids - from animals

C07K 016/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

G01N 033/563 Investigating or analysing materials by specific methods not covered by groups - involving antibody fragments

A61P 025/28 Drugs for disorders of the nervous system

A61K 038/17 Medicinal preparations containing peptides - from animals

A61K 038/20 Medicinal preparations containing peptides - Interleukins

C12N 015/10 Mutation or genetic engineering - Processes for the isolation, preparation or purification of DNA or RNA

G01N 033/536 Investigating or analysing materials by specific methods not covered by groups - with immune complex formed in liquid phase

C07H 021/04 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids